Ocular Therapeutix™ Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
BTIG Downgrades Ocular Therapeutix (OCUL) to Neutral
May 5, 2017 2:35 PM EDTBTIG downgraded Ocular Therapeutix (NASDAQ: OCUL) from Buy to Neutral. Analyst Dane Leone thinks there is risk of a delay in the current PDUFA date for Dextenza.
For an analyst ratings summary and ratings history on Ocular Therapeutix... More
Ocular Therapeutix (OCUL) Misses Q1 EPS by 10c
May 5, 2017 7:33 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.58), $0.10 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $475 thousand versus the consensus estimate of $470 thousand.
This is an important time for Ocular Therapeutix as we approach the PDUFA target action... More
